XERIS BIOPHARMA HOLDINGS, INC. Shareholders' Equity
XERIS BIOPHARMA HOLDINGS, INC. (XERS) had Shareholders' Equity of -$9.73 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent -$9.73M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $13.01M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $13.69M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$861.00K.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | -$9.73M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $13.01M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $13.69M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$861.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$19.30M 10-Q · filed 2026-08-06 |
| 2025-03-31 | -$35.13M 10-Q · filed 2026-08-06 |
| 2024-12-31 | -$29.61M 10-Q · filed 2026-08-06 |
| 2024-09-30 | -$28.32M 10-Q · filed 2025-11-06 |
| 2024-06-30 | -$19.29M 10-Q · filed 2025-11-06 |
| 2024-03-31 | -$9.18M 10-Q · filed 2025-11-06 |
| 2023-12-31 | -$6.78M 10-K · filed 2026-03-02 |
| 2023-09-30 | $3.87M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $13.64M 10-Q · filed 2024-11-08 |
| 2023-03-31 | $30.05M 10-Q · filed 2024-11-08 |
| 2022-12-31 | $45.19M 10-K · filed 2026-03-02 |
| 2022-09-30 | $55.04M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $73.94M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $96.45M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $95.23M 10-K · filed 2025-03-06 |
| 2021-09-30 | -$2.46M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $19.89M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $44.39M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $33.76M 10-K · filed 2024-03-06 |
| 2020-09-30 | $14.34M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $24.38M 10-Q · filed 2021-11-10 |
| 2020-03-31 | $27.07M 10-Q · filed 2021-11-10 |
| 2019-12-31 | $14.44M 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |